Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
Pharmacist called and reported an interrupted dosing series of GARDASIL 9 for an adult patient. Patient received their first dose of GARDASIL 9 in October 2024 and has not yet received any other doses; No additional AE/PQC.; This spontaneous report was received from a pharmacist and refers to a 34-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unspecified date in October 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (dose, route of administration, vaccination site, lot # and expiration date were not reported) administered for prophylaxis. The pharmacist called to report an interrupted dosing series of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). Since October 2024, the patient had not yet received any other doses (inappropriate schedule of product administration). No additional information was known by the reporter. No additional adverse event and no product quality complaint (PQC) was noted (no adverse event). Lot # is being requested and will be submitted if received.